EUCTR2012-000436-25-DK进行中（未招募）1 期
Randomized, double-blinded and placebo-controlled clinical trial of the Rauvolfia-Citrus decoction in patients with type II diabetes - Clinical investigation of the anti-diabetic effects of the Rauvolfia-Citrus decoction
Frederiksberg University Hospital0 个研究点目标入组 250 人开始时间: 2012年6月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with type II diabetes who are 40 years old or more and are taking one or more anti-diabetic treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •The criteria for exclusion of responders to advertisement about the study are T2D patients with:
- •-clinically significant cardiovascular, renal, or liver disease (alanine aminotransferase >3 times the upper limit of normal);
- •-known allergies, heart problems and uncontrolled hypertension (BP > 180/100 mmHg after 5 min rest);
- •-pregnancy, breast-feeding women as well as those women with the possibility of getting pregnant (or not taking contraceptives);
- •-drug abuse or a psychiatric diagnosis or who prove to be difficult to work with during the first interviews.
研究者
相似试验
进行中（未招募）
不适用
Randomized, Double-blind, and Placebo-controlled a Clinical Study for Growing of Stature via the Analysis of Effect of Ferment Oyster Extract : Study ProtocolKCT0004408Pusan National University Korean Medicine Hospital100
进行中（未招募）
1 期
Comparison of the efficacy and safety of rapamycin versus vigabatrin in the prevention of Tuberous Sclerosis Complex symptoms in infants in the randomized clinical trialTuberous Sclerosis ComplexEpilepsyTumors associated with Tuberous Sclerosis ComplexEUCTR2020-003231-19-PLThe Children's Memorial Health Institute60
进行中（未招募）
1 期
A study to test whether different doses of BI 690517 alone or in combination with empagliflozin improve kidney function in people with chronic kidney diseaseMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disorderschronic kidney diseaseEUCTR2021-001434-19-FIBoehringer Ingelheim552
进行中（未招募）
1 期
A study to test whether two different doses of BI 685509 help people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver)portal hypertensionMedDRA version: 20.0Level: HLTClassification code 10036201Term: Portal hypertensionsSystem Organ Class: 100000004866EUCTR2021-001285-38-NLBoehringer Ingelheim bv Netherlands105
进行中（未招募）
1 期
A study to test whether two different doses of BI 685509 help people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver)portal hypertensionMedDRA version: 20.0Level: HLTClassification code 10036201Term: Portal hypertensionsSystem Organ Class: 100000004866EUCTR2021-001285-38-PTBoehringer Ingelheim Portugal, Lda150